MacroGenics Inc ( (MGNX) ) has released its Q3 earnings. Here is a breakdown of the information MacroGenics Inc presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, specializing in the development of innovative antibody-based therapeutics for cancer treatment, leveraging its proprietary suite of antibody technology platforms.
In its latest earnings report for the quarter ended September 30, 2025, MacroGenics, Inc. reported total revenues of $72.8 million, a decrease from $110.7 million in the same quarter of the previous year. The company’s net income for the quarter was $16.8 million, compared to $56.3 million in the prior year, reflecting a significant decline in profitability.
Key financial metrics from the report indicate a substantial drop in collaborative and other agreement revenues, which fell to $53 million from $101.4 million year-over-year. Additionally, product sales were non-existent this quarter compared to $4.1 million in the previous year. However, contract manufacturing revenues saw an increase, reaching $19.8 million from $4.6 million. The company also reported a significant increase in accounts receivable and a new liability related to future royalties, impacting its financial position.
Looking forward, MacroGenics, Inc. remains focused on advancing its proprietary product candidates in clinical development, including lorigerlimab, MGC026, and MGC028. The management anticipates relying on strategic collaborations and potential new capital to support ongoing research and development efforts, aiming to maintain sufficient resources to fund operations for at least the next twelve months.